바카라 꽁 머니 Pep attracts interest from Japanese institutions and others in customized production technology
[by Ji, Yong Jun] HLB Pep (formerly Anygen), a company specializing in the development and production of peptide-based materials, announced on April 16 that it participated in the recent pharmaceutical exhibition ‘CPHI Japan 2025.’ During the event, the company engaged in numerous discussions with a wide range of international buyers, including Japanese pharmaceutical firms and research institutions, regarding the supply and contract development and manufacturing (CDMO) of peptide-based new drug materials.
CPHI is recognized as the world’s largest exhibition for the pharmaceutical and biotechnology industries. held annually in Europe and Asia to showcase the latest global trends and technological advancements in the field. This year’s CPHI Japan attracted participation from over 700 companies from 50 countries around the world. According to HLB Pep, numerous companies expressed strong interest in expanding the supply chain for 바카라 꽁 머니-based novel drug materials, which have recently been in the spotlight for their potential as obesity treatments.
According to HLB Pep, the company operates a GMP-certified facility dedicated to the production of 바카라 꽁 머니 raw materials. Leveraging its proprietary technology, the company is capable of synthesizing and manufacturing high-purity 바카라 꽁 머니s tailored to specific customer requirements. At present, the company supplies materials to multiple Korean pharmaceutical companies and research institutions engaged in 바카라 꽁 머니-based drug development.
바카라 꽁 머니 Pep is also intensifying efforts to expand into the U.S. market, the world's largest market, in addition to strengthening its presence in Japan. In Korea, the company is currently supplying the active ingredient for 'Ganirelix' with approval from the Ministry of Food and Drug Safety, which is preparing to undergo current Good Manufacturing Practice (cGMP) certification review by the U.S. Food and Drug Administration (FDA).
"바카라 꽁 머니 therapeutics possess a promising growth potential as they have great advantages in cost and safety over antibody drugs. In fact, the global market is currently expanding at a rapid pace at an annual rate of over 10%," said Shim Kyung-jae, CEO of HLB Pep. "Our company will strengthen its global sales capabilities in tandem with the expansion of its production facilities while actively diversifying its international sales channels, with a strategic focus on the Japanese and the U.S. markets."